liveBook · Manning

Lead optimization

As explained in Build AI Drug Discovery Pipelines

Lead optimization is the phase of systematically modifying a lead compound to improve its potency, selectivity, developability, and safety properties.

Lead optimization is the drug-discovery phase that modifies a promising lead compound while retaining its core molecular structure. The goal is to improve properties that determine whether it can advance toward preclinical study, especially potency, selectivity, developability, and safety. section 1.4.2 section 1.5

Optimization balances several related drug properties:

  • Efficacy measures the maximum desired effect; potency measures the dose required to produce it, with lower required doses generally preferred. section 1.4.2
  • Selectivity measures binding to the intended target relative to other proteins, while safety and therapeutic index describe the resulting risk profile. section 1.4.2
  • ADMET covers absorption, distribution, metabolism, excretion, and toxicity; unfavorable PK, PD, or toxicity profiles increase clinical-trial failure risk. section 1.4.2

Active learning with free-energy calculations

After identifying promising hits, active learning can support lead optimization by using free-energy calculations to search for compounds with stronger binding affinity and reduced off-target activity. The appropriate computational oracle depends on the use case; docking is one possible earlier-stage technique. section 9.3

Figure 1.11 We can breakdown drug design into target identification and validation, hit discovery, hit-to-lead (lead identification), lead optimization, and preclinical development. Once a drug candidate has progressed to the drug development stage, it will need to pass multiple phases of clinical trials testing safety and efficacy prior to submission to and review by the FDA and launch to market.

Use the pipeline diagram to place lead optimization between lead identification and preclinical development, followed by clinical testing for safety and efficacy. section 1.4

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines property goals and introduces computational free-energy experiments, without detailing a complete medicinal-chemistry optimization protocol.
Examples
Uses free-energy calculations and active learning to improve binding affinity and reduce off-target activity after hit discovery.
What you can do after
Apply active learning and free-energy calculations to prioritize molecular improvements during lead optimization.
How it connects
Connects lead optimization to hit discovery, lead identification, pharmacokinetics, pharmacodynamics, ADMET, docking, and active learning.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.